Padecimientos

Hemos juntado un listado amplio de todas las condiciones beneficias por el uso de extracto de cannabinoides.

Hemos identificado una lista de padecimientos con amplia documentación medica y estudios científicos que establecen el beneficio que representa el uso de extractos cannabinoides. El estudio científico da una validez dentro de la comunidad médica y comprueba al paciente candidato que puede mejorar su calidad de vida y reducir los síntomas asociados con estos padecimientos entre otros.

  • Alzheimer
  • Artritis
  • Cancer y síntomas de quimioterapia / radiacion
  • Depresion / ansiedad / insomnio
  • Diabetes
  • Epilepsia
  • Esclerosis múltiple
  • Glaucoma
  • Parkinson
  • HIV

Evidencia clínica científica

Cáncer

Cáncer general

CBD como potencial medicina anticáncer: https://www.ncbi.nlm.nih.gov/pubmed/22506672

CBD inhibe la angiogénesis por medio de múltiples mecanismos: https://www.ncbi.nlm.nih.gov/pubmed/22624859

CBD inhibe la invasión de células cancerígenas por medio de proteinasas: https://www.ncbi.nlm.nih.gov/pubmed/19914218

La marihuana combate al cáncer y ayuda a sus efectos colaterales: http://www.thedailybeast.com/marijuana-fights-cancer-and-helps-manage-side-effects-researchers-find

La influencia de las propiedades biomecánicas de los cannabinoides en la invasión tumoral: https://www.ncbi.nlm.nih.gov/pubmed/27149140

Sitios antitumorales de los cannabinoides: https://www.ncbi.nlm.nih.gov/pubmed/27070944

Los cannabinoides, ¿una nueva herramienta contra el cáncer?: https://www.ncbi.nlm.nih.gov/pubmed/28100841

Cáncer de vejiga

Apoptosis de células cancerígenas de vejiga en el humano, el papel de la activación TRPV2: https://www.ncbi.nlm.nih.gov/pubmed/20546877

Cáncer de cerebro

Cannabidiol potencia el efecto inhibidor del THC sobre glioblastoma: https://www.ncbi.nlm.nih.gov/pubmed/20053780

Efecto antitumor del CBD, un cannabinoide no psicoactivo sobre las células malignas de Glioma: https://www.ncbi.nlm.nih.gov/pubmed/15700028

Cannabis mejora la sobrevida en pacientes con tumores malignos en el cerebro: http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=499#1

CBD inhibe la migración celular en Gliomas de humanos: https://www.ncbi.nlm.nih.gov/pubmed/15700028

Cáncer de mama

Actividad anticancerígena de los cannabinoides sobre el cáncer de mama en humanos: https://www.ncbi.nlm.nih.gov/pubmed/16728591

Cannabidiol (CBD) induce a la muerte celular de célular cancerígenas en el cáncer de mama: https://www.ncbi.nlm.nih.gov/pubmed/21566064

Vías metabólicas implicadas del CBD para la reducción proliferativa de células malignas, invasión y metástasis en cáncer de mama: https://www.ncbi.nlm.nih.gov/pubmed/20859676

CBD como inhibidor del Gen Id-1 de las células malignas de cáncer de mama: https://www.ncbi.nlm.nih.gov/pubmed/18025276

Acido cannabidiólico como inhibidor de la migración maligna: https://www.ncbi.nlm.nih.gov/pubmed/22963825

Cáncer de colon

Efecto Quimioprotector del Cannabidiol en cáncer de colon: https://www.ncbi.nlm.nih.gov/pubmed/22231745

Inhibición de la carcinogénesis proveniente de colon con extracto de cannabis sativa rico en CBD: http://www.phytomedicinejournal.com/article/S0944-7113%2813%2900472-8/abstract

Apoptosis inducida por CBD en cáncer de colon y próstata: https://www.ncbi.nlm.nih.gov/pubmed/22110202

Cáncer de pulmón

Cannabidiol inhibe la invasión y metástasis de células cancerosas de pulmón por la vía molécula-1C de adhesión intercelular: https://www.ncbi.nlm.nih.gov/pubmed/22198381

COX2 y PPAR-ϒ comprueban la apoptosis de células malgnas de cáncer de pulmón inducida por cannabidiol: https://www.ncbi.nlm.nih.gov/pubmed/23220503

La disminución del inhibidor del activador de plasminógeno puede contribuir a la acción anti-invasiva del CBD en cáncer de pulmón: https://www.ncbi.nlm.nih.gov/pubmed/20668920

La marihuana ayuda a prevenir el cáncer de pulmón, ahora ya es material de estudio en escuelas de medicina: http://www.alternet.org/drugs/media-ignored-experts-shocking-findings-marijuana-helps-prevent-lung-cancer-now-its-med-school

Leucemia

Apoptosis inducida por CBD en células leucémicas humanas: https://www.ncbi.nlm.nih.gov/pubmed/16754784

Dolor por cáncer

Eficacia, seguridad y tolerabilidad de extracto rico en THC; CBD y THC puro en pacientes con cáncer con dolor intratable: https://www.ncbi.nlm.nih.gov/pubmed/19896326

Cannabinoides transnasales para pacientes con cáncer tratado con opioides con dolor crónico mal controlado: https://www.ncbi.nlm.nih.gov/pubmed/22483680

El extracto de marihuana previene dolor por quimioterapia: http://www.upi.com/health_news/2011/09/27/marijuana-extract-helps-prevent-chemo-pain/UPI-64641317159672

Dolor crónico

Meta-análisis sobre tratamientos a base de cannabinoides para dolor neuropático y dolor por esclerosis múltiple: https://www.ncbi.nlm.nih.gov/pubmed/17257464

Sativex®; clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain: https://www.ncbi.nlm.nih.gov/pubmed/16553576

Cannabis, pain and sleep; lessons from therapeutic clinical trials of Sativex®, a cannabis-based medicine: https://www.ncbi.nlm.nih.gov/pubmed/17712817

Sativex® successfully treats neuropathic pain characterised by allodynia; a randomised, double-blind, placebo-controlled clinical trial: https://www.ncbi.nlm.nih.gov/pubmed/17997224

Cannabinoids for neuropathic pain: https://www.ncbi.nlm.nih.gov/pubmed/25160710

Neuropathic orofacial pain; cannabinoids as a therapeutic avenue: https://www.ncbi.nlm.nih.gov/pubmed/25150831

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis; an uncontrolled, open-label, 2-year extension trial: https://www.ncbi.nlm.nih.gov/pubmed/18035205

The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain: https://www.ncbi.nlm.nih.gov/pubmed/17157290

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the non-psychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation: https://www.ncbi.nlm.nih.gov/pubmed/15313881

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT (1A) receptors without diminishing nervous system function or chemotherapy efficacy: https://www.ncbi.nlm.nih.gov/pubmed/24117398

Antihyperalgesic effect of a cannabis sativa extract in a rat model of neuropathic pain; mechanisms involved: https://www.ncbi.nlm.nih.gov/pubmed/18618522

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action: https://www.ncbi.nlm.nih.gov/pubmed/20942863

Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors: https://www.ncbi.nlm.nih.gov/pubmed/22585736

Roleofthe cannabinoid system in pain control and therapeutic implications for the managementof acute and chronic pain episodes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430692/

Cannabinoids in the management of difficult to treat pain: https://www.ncbi.nlm.nih.gov/pubmed/18728714

Pot users less likely to take painkillers: http://americannewsreport.com/pot-users-less-lilely-to-take-painkillers-8818306

Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats: https://www.ncbi.nlm.nih.gov/pubmed/28680401

Depresión

Endocannabinoid system dysfunction in mood and related disorders: https://www.ncbi.nlm.nih.gov/pubmed/21916860

Antidepressant-like and anxiolytic-like effects of cannabidiol; a chemical compound of cannabis sativa: https://www.ncbi.nlm.nih.gov/pubmed/24923339

The endocannabinoid system and the treatment of mood and anxiety disorders: https://www.ncbi.nlm.nih.gov/pubmed/19839936

Endocannabinoid signaling in the etiology and treatment of major depressive illness: https://www.ncbi.nlm.nih.gov/pubmed/24180398

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors: https://www.ncbi.nlm.nih.gov/pubmed/20002102

Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants: https://www.ncbi.nlm.nih.gov/pubmed/21111017

Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from cannabis sativa L: https://www.ncbi.nlm.nih.gov/pubmed/20332000

Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress: https://www.ncbi.nlm.nih.gov/pubmed/19394765

Serum contents of endocannabinoids are correlated with blood pressure in depressed women: https://www.ncbi.nlm.nih.gov/pubmed/22373123

The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants: https://www.ncbi.nlm.nih.gov/pubmed/19732971

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors: https://www.ncbi.nlm.nih.gov/pubmed/26711860

Prohedonic effect of cannabidiol in a rat model of depression: https://www.ncbi.nlm.nih.gov/pubmed/27010632

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of cannabis sativa: https://www.ncbi.nlm.nih.gov/pubmed/24923339

Enfermedad de Parkinson

Effects of cannabidiol in the treatment of patients with Parkinson’s disease; an exploratory double-blind trial: https://www.ncbi.nlm.nih.gov/pubmed/25237116

Prospects for cannabinoid therapies in basal ganglia disorders: https://www.ncbi.nlm.nih.gov/pubmed/21545415

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease; importance of antioxidant and cannabinoid receptor-independent properties: https://www.ncbi.nlm.nih.gov/pubmed/17196181

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro; relevance to Parkinson’s disease: https://www.ncbi.nlm.nih.gov/pubmed/15837565

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movementsleep behaviour disorder in Parkinson’s disease patients; a case series: https://www.ncbi.nlm.nih.gov/pubmed/24845114

Cannabidiol for the treatment of psychosis in Parkinson’s disease https://www.ncbi.nlm.nih.gov/pubmed/18801821

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease: https://www.ncbi.nlm.nih.gov/pubmed/21323909

Therapeutic potential of cannabinoids in CNS disease: https://www.ncbi.nlm.nih.gov/pubmed/12617697

Neurological aspects of medical use of cannabidiol: https://www.ncbi.nlm.nih.gov/pubmed/28412918

Epilepsia

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy: https://www.ncbi.nlm.nih.gov/pubmed/24237632

Cannabinoids for epilepsy: https://www.ncbi.nlm.nih.gov/pubmed/22696383

Cannabis, cannabidiol, and epilepsy–from receptors to clinical response: https://www.ncbi.nlm.nih.gov/pubmed/25282526

Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro; potential for the treatment of neuronal hyperexcitability: http://pubs.acs.org/doi/pdf/10.1021/cn5000524

Chronic administration of cannabidiol to healthy volunteers and epileptic patients: https://www.ncbi.nlm.nih.gov/pubmed/7413719

Endocannabinoid system protects against cryptogenic seizures: https://www.ncbi.nlm.nih.gov/pubmed/21441624

Seizing an opportunity for the endocannabinoid system: https://www.ncbi.nlm.nih.gov/pubmed/25346637

Cannabidiol: promise and pitfalls: https://www.ncbi.nlm.nih.gov/pubmed/25346628

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatricdisorders: https://www.ncbi.nlm.nih.gov/pubmed/24854329

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840466/pdf/peerj-01-214.pdf

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures: https://www.ncbi.nlm.nih.gov/pubmed/22520455

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo: https://www.ncbi.nlm.nih.gov/pubmed/19906779

Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure: https://link.springer.com/article/10.1007%2Fs12031-015-0703-6

Pharmacology of cannabinoids in the treatment of epilepsy: https://www.ncbi.nlm.nih.gov/pubmed/28087250

Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection: https://www.ncbi.nlm.nih.gov/pubmed/28190698

Report from a survey of parents regarding the use of cannabidiol (medicinal cannabis) in mexican children with refractory epilepsy: https://www.ncbi.nlm.nih.gov/pubmed/28392943

Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy: https://www.ncbi.nlm.nih.gov/pubmed/28367124

Alzheimer

Cannabinoides como proteínas protectoras que se forman en el Cerebro: https://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/

Estudios en CBD y enfermedad de Alzheimer:    https://www.projectcbd.org/alzheimers-disease

Artritis

Cannabinoids and Rheumatoid Arthritis: What Research Says: https://echoconnection.org/cannabinoids-rheumatoid-arthritis-research-says/

Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with

Osteoarthritis of the Knee Joint – http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0080440&type=printable

Insomnia

Cannabis, Cannabinoides y Sueno – Revisemos los estudios – https://link.springer.com/article/10.1007%2Fs11920-017-0775-9

Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults – https://www.ncbi.nlm.nih.gov/pubmed/15118485

Diabetes

The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults – http://www.amjmed.com/article/S0002-9343%2813%2900200-3/abstract

Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes – https://www.ncbi.nlm.nih.gov/pubmed/21484568

 

The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications – https://www.ncbi.nlm.nih.gov/pubmed/22155112

Esclerosis Multiple

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain – https://www.ncbi.nlm.nih.gov/pubmed/17257464

Sativex for the management of multiple sclerosis symptoms –  https://www.ncbi.nlm.nih.gov/pubmed/16317825